热门资讯> 正文

免疫工程在治疗胰腺癌的孤儿药物指定中崛起

2024-10-15 21:04

Immuneering Corporation (NASDAQ:IMRX) shares up 24.5% premarket after it announced that the U.S. FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer.
IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer.
Source: Press Release

More on Immuneering, Teva Pharmaceutical, etc.

Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference (Transcript)
Cheap Teva Stock Should Reward Patient Investors
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Teva agrees to pay $425M to settle Copaxone kickback case: DOJ
TEVA applications for Prolia biosimilar accepted by FDA, EMA

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。